A list of FDA approved GLP1s

The world GLP1 Receptor Agonists is moving quickly. While most people are familiar with the popular variants of the drug – Ozempic, Wegovy, Mounjaro and others – many do not know all the options available.

The List

The list of current FDA approved GLP1s

Many drugs are still under development

An important part of enabling more people who want access to GLP1s is having more, new formulations that are effective on the market.

There are many new drugs under development that are not yet FDA approved but are worth keeping an eye on. Here are some we've covered in the past, created by large and small pharmaceutical companies:

Novo’s new GLP1: Amycretin

Novo has a new drug it’s working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.

GLP1 GuideGLP1.Guide Staff

A new GLP1: Retatrutide

Is mimicking more hormones better? Let’s find out -- the new GLP1 drug Retatrutide is a *triple* receptor agonist

GLP1 GuideGLP1.Guide Staff

Viking Therapeutic’s new GLP1 produces oustanding results

At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.

GLP1 GuideGLP1.Guide Staff

Source: The FDA

So where did we find this fairly comprehensive list? We were delighted to find a great listing of all the currently FDA-approved GLP1s on the market in a recent announcement by the FDA:

Update on FDA’s ongoing evaluation of GLP-1 RAs and Suicidality

Preliminary evaluation does not suggest a causal link

FDACenter for Drug Evaluation and Research

While the post itself contained great news – that GLP1s were not causatively linked to any distinct increases in anxiety/depression amongst users – we found the list to be particularly useful.